1 hour ago
Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.
1 hour ago
The FDA has approved RNA interference therapeutic plozasiran for the treatment of familial chylomicronemia syndrome.
2 hours ago
Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.
2 hours ago
New qualitative findings reveal the underrecognized psychosocial burdens facing children with HAE and the unmet needs shaping their care.
3 hours ago
Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.